

January 17, 2017

To,  
Dy. General Manager  
Department of Corporate Services,  
Bombay Stock Exchange Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

We have to inform you that a meeting of the Board of Directors will be held on Thursday, February 02, 2017 to consider and approve the Company's Unaudited Financial Statements for the Third Quarter and Nine months ended December 31, 2016.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 26, 2016 to February 06, 2017 (both days inclusive) for the purpose of approval of Unaudited Financial Statements for the Third Quarter and Nine months ended December 31, 2016.

The above is for your information.

Thanking you.

Yours faithfully,  
For Glenmark Pharmaceuticals Limited



**Rajesh V. Desai**  
Executive Director

Tel: 4018 9999 / 4018 9879  
Fax: 4018 9986 (Legal & Secretarial Dept.)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)